Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits

Jennifer Glass, Krista L Lanctôt, Nathan Herrmann, Beth A Sproule, Usoa E Busto, Jennifer Glass, Krista L Lanctôt, Nathan Herrmann, Beth A Sproule, Usoa E Busto

Abstract

Objectives: To quantify and compare potential benefits (subjective reports of sleep variables) and risks (adverse events and morning-after psychomotor impairment) of short term treatment with sedative hypnotics in older people with insomnia.

Data sources: Medline, Embase, the Cochrane clinical trials database, PubMed, and PsychLit, 1966 to 2003; bibliographies of published reviews and meta-analyses; manufacturers of newer sedative hypnotics (zaleplon, zolpidem, zopiclone) regarding unpublished studies.

Selection criteria: Randomised controlled trials of any pharmacological treatment for insomnia for at least five consecutive nights in people aged 60 or over with insomnia and otherwise free of psychiatric or psychological disorders.

Results: 24 studies (involving 2417 participants) with extractable data met inclusion and exclusion criteria. Sleep quality improved (effect size 0.14, P < 0.05), total sleep time increased (mean 25.2 minutes, P < 0.001), and the number of night time awakenings decreased (0.63, P < 0.001) with sedative use compared with placebo. Adverse events were more common with sedatives than with placebo: adverse cognitive events were 4.78 times more common (95% confidence interval 1.47 to 15.47, P < 0.01); adverse psychomotor events were 2.61 times more common (1.12 to 6.09, P > 0.05), and reports of daytime fatigue were 3.82 times more common (1.88 to 7.80, P < 0.001) in people using any sedative compared with placebo.

Conclusions: Improvements in sleep with sedative use are statistically significant, but the magnitude of effect is small. The increased risk of adverse events is statistically significant and potentially clinically relevant in older people at risk of falls and cognitive impairment. In people over 60, the benefits of these drugs may not justify the increased risk, particularly if the patient has additional risk factors for cognitive or psychomotor adverse events.

Figures

Fig 1
Fig 1
Flowchart for identification of studies
Fig 2
Fig 2
Mean effect size (95% confidence intervals) for subjective improvements in sleep quality with any sedative treatment and benzodiazepines only compared with placebo for at least five nights in people aged 60 or older with insomnia
Fig 3
Fig 3
Cognitive and psychomotor adverse events, odds ratios, z scores, and test for heterogeneity for any sedative hypnotics taken for at least five nights in people aged 60 or older with insomnia

References

    1. Brostrom A, Stromberg A, Dahlstrom U, Fridlund B. Sleep difficulties, daytime sleepiness, and health-related quality of life in patients with chronic heart failure. J Cardiovasc Nurs 2004;19: 234-42.
    1. Byles JE, Mishra GD, Harris MA, Nair K. The problems of sleep for older women: changes in health outcomes. Age Ageing 2003;32: 154-63.
    1. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6: 97-111.
    1. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. The diagnosis and management of insomnia in clinical practice: a practical evidence-based approach. CMAJ 2000;162: 206-10.
    1. Aparasu RR, Mort JR, Brandt H. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc 2003;51: 671-7.
    1. Craig D, Passmore AP, Fullerton KJ, Beringer TR, Gilmore DH, Crawford VL, et al. Factors influencing prescription of CNS medications in different elderly populations. Pharmacoepidemiol Drug Saf 2003;12: 383-7.
    1. Barbone F, McMahon AD, Davey PG, Morris AD, Reid IC, McDevitt DG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998;352: 1331-6.
    1. Neutel CI, Perry S, Maxwell C. Medication use and risk of falls. Pharmacoepidemiol Drug Saf 2002;11: 97-104.
    1. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189-98.
    1. Fleming JAE. Insomnia. In: Gray J, ed. Therapeutic choices. Ottawa: Canadian Pharmacists Association, 2003: 54-62.
    1. Jadad A, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17: 1-12.
    1. Holbrook A, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000;162: 225-33.
    1. McAlister FA, Straus SE, Guyatt GH, Haynes RB. Users' guides to the medical literature. XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group. JAMA 2000;283: 2829-36.
    1. De Craen AJ, Vickers AJ, Tijssen JG, Kleijnen J. Number-needed-to-treat and placebo-controlled trials. Lancet 1998;351: 310.
    1. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50: 1088-101.
    1. Cochrane collaboration open learning material. Module 15. 2002. (accessed Mar 2004).
    1. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56: 455-63.
    1. Ancoli-Israel S, Walsh JK, Mangano RM, Fujimori M. Zaleplon A. Novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Prim Care Companion J Clin Psychiatry 1999;1: 114-20.
    1. Bayer AJ, Pathy MS, Ankier SI. An evaluation of the short-term hypnotic efficacy of loprazolam in comparison with nitrazepam in elderly patients. Pharmatherapeutica 1983;3: 468-74.
    1. Bayer A, Pathy MSJ. Clinical and psychometric evaluation of 2 doses of loprazolam and placebo in geriatric patients. Curr Med Res Opinion 1986;10: 17-24.
    1. Dehlin O, Bjornson J. Triazolam as a hypnotic for geriatric patients. Act Psychiatr Scand 1983;67: 290-6.
    1. Dehlin O, Rubin B, Rundgren A. Double-blind comparison of zopiclone and flunitrazepam in elderly insomniacs with special focus on residual effects. Curr Med Res Opinion 1995;13: 317-24.
    1. Elie R, Frenay M, Le Morvan P, Bourgouin J. Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs. Int Clin Psychopharmacol 1990;5(suppl 2): 39-46.
    1. Fairweather DB, Kerr JS, Hindmarch I. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin Pharmacol 1992;43: 597-601.
    1. Hedner J, Yaeche R, Emilien G, Farr I, Salinas E. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatry 2000;15: 704-12.
    1. Klimm H, Dreyfus JF, Delmotte M. Zopiclone vs. nitrazepam: a double-blind comparative study of efficacy and tolerance in elderly patients with chronic insomnia. Sleep 1987;10: 73-8.
    1. Lachnit K, Proszolowski E, Rieder L. Midazolam in the treatment of sleep disorders in geriatric patients. Br J Clin Pharmac 1983;16 (suppl): 173-7S.
    1. Leppik I, Roth-Schecheter GB, Gray GW, Cohn MA, Owens D. Double-blind, placebo-controlled comparison of zolpidem, triazolam, and temazepam in elderly patients with insomnia. Drug Dev Res 1997;40: 230-8.
    1. Mamelak M, Csima A, Buck L, Price V. A comparative study on the effects of brotizolam and flurazepam on sleep and performance in the elderly. J Clin Psychopharm 1989;9: 260-7.
    1. Meuleman JR, Nelson RC, Clark RL Jr. Evaluation of temazepam and diphenhydramine as hypnotics in a nursing-home population. Drug Intell Clin Pharm 1987;21: 716-20.
    1. Morin C, Colecchi C, Stone J, Sood R, Brink D. Behavioural and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999;281: 991-9.
    1. Murphy P, Hindmarch I, Hyland CM. Aspects of short-term use of two benzodiazepine hypnotics in the elderly. Age Ageing 1982;11: 222-8.
    1. Overstall P, Oldman PN. A comparative study of lormetazepam and chlormethiazole in elderly in-patients. Age Ageing 1987;16: 45-51.
    1. Reeves R. Comparison of triazolam, flurazepam, and placebo as hypnotics in geriatric patients with insomnia. J Clin Pharmacol 1977;17: 319-23.
    1. Richards HH, Valle-Jones CJ. A double-blind comparison of two lormetazepam doses in elderly insomniacs. Curr Med Res Opin 1988;11: 48-55.
    1. Roger M, Attali R, Coquelin JP. Multicentre, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin Therapeutics 1993;15: 127-36.
    1. Viukari M, Vartio T, Verho E. Low doses of brotizolam and nitrazepam as hypnotics in the elderly. Neuropsychobiol 1984;12: 130-3.
    1. Bayer A, Bayer EM, Pathy MSJ, Stoker MJ. A double-blind controlled study of chlomethiazole and triazolam as hypnotics in the elderly. Acta Psychiatr Scand 1986;73: 104-11.
    1. Caldwell JR. Short-term quazepam treatment of insomnia in geriatric patients. Pharmatherapeutica 1982;3: 278-82.
    1. Mouret J, Ruel D, Maillard F, Bianchi M. Zopiclone versus triazolam in insomniac geriatric patients: a specific increase in delta sleep with zopiclone. Int Clin Psychopharmacol 1990;5(suppl 2): 47-55.
    1. Roth T, Roehrs TA, Ksohorek GL, Greenblatt DJ, Rosenthal LD. Hypnotic effects of low doses of quazepam in older insomniacs. J Clin Psychopharmacol 1997;17: 401-6.
    1. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Earlbaum, 1988.
    1. Nowell PM, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF 3rd, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997;278: 2170-7.
    1. Smith MT, Perlis ML, Park A, Smith MS, Pennington J, Giles DE, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 2002;159: 5-11.
    1. Wysowski D, Barash D. Adverse behavioural reactions attibuted to triazolam in the Food and Drug Administration's spontaneous reporting system. Arch Intern Med 1991;151: 3003-8.
    1. American Sleep Disorders Association. International classification of sleep disorders diagnostics and coding manual. Rochester, MN: ASDA, 1990.
    1. Mort JR, Aparasu RR. Prescribing of psychotropics in the elderly: why is it so often inappropriate? CNS Drugs 2002;16: 99-109.
    1. Kallin K, Jensen J, Olsson LL, Nyberg L, Gustafson Y. Why the elderly fall in residential care facilities, and suggested remedies. J Fam Pract 2004;53: 41-52.
    1. Greenblatt D, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI. Sensitivity to triazolam in the elderly. N Engl J Med 1991;324: 1691-8.
    1. Greenblatt D, Shader RI, Harmatz JS. Implications of altered drug disposition in the elderly: studies of benzodiazepines. J Clin Pharmacol 1989;29: 866-72.
    1. Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Shader RI. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther 2004;76: 467-79.
    1. Hemmelgarn B, Suissa S, Huang A, Boivin J, Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 1997;278: 27-31.
    1. Ray W. Safety and mobility of the older driver. JAMA 1997;278: 66.
    1. Kripke DF, Hauri P, Ancoli-Israel S, Roth T. Sleep evaluation in chronic insomniacs during 14-day use of flurazepam and midazolam. J Clin Psychopharmacol 1990;10(suppl): 32-43S.
    1. Morin C, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatement efficacy. Am J Psychiatry 1994;151: 1172-80.
    1. Murtagh D, Greenwood KM. Identifying effective psychological treatments for insomnia: a meta-analysis. J Consult Clin Psychol 1995;63: 79-89.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다